Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Condie, C. K.
Right arrow Articles by Canann, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Condie, C. K.
Right arrow Articles by Canann, D. M.
American Journal of Health-System Pharmacy, Vol. 65, Issue 5, 454-457
Copyright © 2008. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00


Notes

Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery

Chad K. Condie, Linda S. Tyler, Brian Barker and David M. Canann

CHAD K. CONDIE, PHARM.D., is Clinical Pharmacist, University of Utah Healthcare (UUH), Salt Lake City. LINDA S. TYLER, PHARM.D., FASHP, is Director, Drug Information Service, UUH, and Professor (Clinical), Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City. BRIAN BARKER, B.S.PHARM., is Clinical Pharmacist, and DAVID M. CANANN, PHARM.D ., is Clinical Pharmacist, UUH.

Address correspondence to Dr. Condie at the Department of Pharmacy Services, Room A-050, University of Utah Hospital, 50 North Medical Drive, Salt Lake City, UT 84132.


Purpose. The physical compatibility of i.v. caspofungin with other commonly used i.v. medications was tested.

Methods. Two methods were used to combine caspofungin and the secondary drugs. For drugs administered by i.v. push, caspofungin was delivered through a poly-vinyl chloride (PVC) i.v. solution set with secondary drugs injected into the Y-site of the i.v. extension set. For drugs given by i.v. infusion (over 10 minutes), secondary drugs were infused into the Y-site of the i.v. solution set through microbore PVC tubing. The two drugs shared 39 in of tubing. Attached to each end of the i.v. extension set were 0.8-µm filter disks. All drug combinations were tested three times; after each infusion, the filters were bubble-point tested. Drug combinations were considered physically compatible if no visible precipitate was seen and no color change was noted by the unaided eye during the infusion, or if the number of particles found on the filter under a microscope did not exceed the number stated in United States Pharmacopeia guidelines for particulate levels of large-volume parenteral fluids.

Results. A total of 8 of the 31 drugs tested (acyclovir, ceftriaxone, cefazolin, clindamycin, furosemide, heparin, pantoprazole, and piperacillin–tazobactam) were found to be physically incompatible with caspofungin.

Conclusion. Caspofungin acetate was physically compatible during Y-site injection with 23 of 31 medications tested.

Index terms: Antifungals; Caspofungin acetate; Incompatibilities; Injections; Poly-vinyl chloride; Stability; Tubing

 



This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
D. Canann, L. S. Tyler, B. Barker, and C. Condie
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am. J. Health Syst. Pharm., April 15, 2009; 66(8): 727 - 729.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
D. W. Newton
Membrane-filter bubble-point test
Am. J. Health Syst. Pharm., December 1, 2008; 65(23): 2210 - 2212.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Health-System Pharmacists.